Stockscreener 앱 받기
28.11
0.38%
-0.0613
Castle Biosciences Inc 주식(CSTL)의 최신 뉴스
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB - The Manila Times
Melanoma test may let some patients skip lymph node surgery - Stock Titan
Castle Biosciences (NASDAQ:CSTL) Lowered to Hold Rating by Zacks Research - MarketBeat
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas - Bitget
CSTL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Canaccord reiterates Castle Biosciences stock rating on Q4 beat By Investing.com - Investing.com India
Canaccord reiterates Castle Biosciences stock rating on Q4 beat - Investing.com
Aug Volume: What is the target price for Seer Inc stockEarnings Beat & Community Shared Stock Ideas - baoquankhu1.vn
Q4 2025 Castle Biosciences Inc Earnings Call Transcript - GuruFocus
Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2025 Earnings Call Transcript - Insider Monkey
Castle Biosciences, Inc. (CSTL) Stock Analysis: Unveiling a Promising 50.96% Upside for Investors - DirectorsTalk Interviews
Castle Biosciences (NASDAQ:CSTL) Shares Gap DownWhat's Next? - MarketBeat
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down - Finviz
Castle Biosciences (CSTL) Analyst Rating Update: Baird Raises Pr - GuruFocus
Robert W. Baird Forecasts Strong Price Appreciation for Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
Expert Outlook: Castle Biosciences Through The Eyes Of 6 Analysts - Benzinga
Castle Biosciences, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:CSTL) 2026-02-27 - Seeking Alpha
Castle Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Castle Biosciences Inc (CSTL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges - GuruFocus
Transcript : Castle Biosciences, Inc., Q4 2025 Earnings Call, Feb 26, 2026 - marketscreener.com
Volatility Watch: Will Castle Biosciences Inc stock go up in YEAR2025 Bull vs Bear & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Castle Biosciences (NASDAQ:CSTL) Releases Earnings Results - MarketBeat
Castle Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Castle Biosciences Q4 2025 slides: test volumes surge 42%, enters AD market - Investing.com
Castle Biosciences (CSTL) Earnings Transcript - AOL.com
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Castle Biosciences Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Castle Biosciences Q4 2025 beats expectations, stock rises - Investing.com
Earnings Flash (CSTL) Castle Biosciences, Inc. Reports Q4 Revenue $87.0M, vs. FactSet Est of $79.9M - marketscreener.com
Castle Biosciences Posts Modest 2025 Growth Amid Headwinds - TipRanks
Earnings Flash (CSTL) Castle Biosciences, Inc. Posts Q4 Adjusted Loss $0.08 per Share, vs. FactSet Est of $-0.26 - marketscreener.com
Castle Biosciences Reports 37% Increase in Core Test Reports for 2025, Achieving $344 Million in Revenue - Quiver Quantitative
Castle Biosciences (CSTL) swings to 2025 loss as margins compress - Stock Titan
Skin cancer test maker lifts core volumes 37%, ends 2025 with $24.2M loss - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Castle Biosciences Stock Hits Day Low of $27.80 Amid Price Pressure - Markets Mojo
Exploring Castle Biosciences's Earnings Expectations - Benzinga
RTW INVESTMENTS, LP Acquires Significant Stake in Castle Bioscie - GuruFocus
Castle Biosciences, Inc. (CSTL) Stock Report: Analysts See 54.98% Potential Upside Amidst Innovative Diagnostics - DirectorsTalk Interviews
Castle Biosciences Publishes Study Demonstrating AdvanceAD-Tx Test Improves Treatment Outcomes for Moderate-to-Severe Atopic Dermatitis Patients - Quiver Quantitative
Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis - The Manila Times
New skin test steers severe eczema patients to faster JAK drug relief - Stock Titan
Castle Biosciences (NASDAQ:CSTL) Stock Price Down 7%Should You Sell? - MarketBeat
Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Yahoo Finance
Castle Biosciences (CSTL) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Prospective Validation Study in JAAD Demonstrates Castle Biosciences' AdvanceAD-Tx Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis - Bitget
Can Castle Biosciences Inc. maintain its current growth rateRecession Risk & Precise Trade Entry Recommendations - mfd.ru
RTW Investments reveals 7.2% Castle Biosciences (CSTL) stake in 13G filing - Stock Titan
How do insiders feel about Castle Biosciences Inc2025 Market Outlook & Verified High Yield Trade Plans - baoquankhu1.vn
Aug Weekly: Why is CKPT stock going upJuly 2025 Action & Daily Entry Point Trade Alerts - baoquankhu1.vn
Castle Biosciences, Inc. (CSTL) Stock Analysis: A Promising 52% Upside with Strong Buy Ratings - DirectorsTalk Interviews
Castle Biosciences (CSTL) loses 16.8% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Castle Biosciences stock jumps after FDA grants Breakthrough Device status to melanoma test - MSN
EV Market: Can Castle Biosciences Inc deliver alpha2025 Stock Rankings & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Aug Weekly: Can Castle Biosciences Inc. maintain its current growth rateEarnings Overview Report & Long-Term Investment Growth Plans - baoquankhu1.vn
Castle Biosciences (CSTL) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Finviz
Castle Biosciences, Inc. $CSTL Shares Sold by Allianz Asset Management GmbH - MarketBeat
Castle Biosciences, Inc. (CSTL) Stock Analysis: Exploring a 49.91% Upside Potential for Investors - DirectorsTalk Interviews
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 3,200 Shares of Stock - MarketBeat
Derek Maetzold Sells 817 Shares of Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
What Catalysts Are Rewriting The Castle Biosciences (CSTL) Story For Wall Street Analysts - Yahoo Finance
1.62%
0.12%
자본화:
|
볼륨(24시간):